Your browser doesn't support javascript.
loading
Development of a novel NURR1/NOT agonist from hit to lead and candidate for the potential treatment of Parkinson's disease.
Lesuisse, Dominique; Malanda, André; Peyronel, Jean-François; Evanno, Yannick; Lardenois, Patrick; De-Peretti, Danielle; Abécassis, Pierre-Yves; Barnéoud, Pascal; Brunel, Pascale; Burgevin, Marie-Claude; Cegarra, Céline; Auger, Florian; Dommergue, Amélie; Lafon, Corinne; Even, Luc; Tsi, Joanna; Luc, Thy Phuong Hieu; Almario, Antonio; Olivier, Anne; Castel, Marie-Noëlle; Taupin, Véronique; Rooney, Thomas; Vigé, Xavier.
Afiliação
  • Lesuisse D; Rare and Neurologic Disease Research, Sanofi, 1 av Pierre Brossolette, Chilly Mazarin F-91935, France. Electronic address: dominique.lesuisse@sanofi.com.
  • Malanda A; Medicinal Chemistry, Sanofi, 1 av Pierre Brossolette, Chilly Mazarin F-91385, France.
  • Peyronel JF; Medicinal Chemistry, Sanofi, 1 av Pierre Brossolette, Chilly Mazarin F-91385, France.
  • Evanno Y; Medicinal Chemistry, Sanofi, 1 av Pierre Brossolette, Chilly Mazarin F-91385, France.
  • Lardenois P; Medicinal Chemistry, Sanofi, 1 av Pierre Brossolette, Chilly Mazarin F-91385, France.
  • De-Peretti D; Medicinal Chemistry, Sanofi, 1 av Pierre Brossolette, Chilly Mazarin F-91385, France.
  • Abécassis PY; DMPK, Sanofi, 13 quai Jules Guesde, Vitry-sur-Seine F-94403, France.
  • Barnéoud P; Rare and Neurologic Disease Research, Sanofi, 1 av Pierre Brossolette, Chilly Mazarin F-91935, France.
  • Brunel P; Preclinical Safety, Sanofi, 3, digue d' Alfortville, Alfortville F-94140, France.
  • Burgevin MC; Translational Science, Sanofi, 1 av Pierre Brossolette, Chilly Mazarin F-91385, France.
  • Cegarra C; Rare and Neurologic Disease Research, Sanofi, 1 av Pierre Brossolette, Chilly Mazarin F-91935, France.
  • Auger F; Medicinal Chemistry, Sanofi, 1 av Pierre Brossolette, Chilly Mazarin F-91385, France.
  • Dommergue A; Medicinal Chemistry, Sanofi, 1 av Pierre Brossolette, Chilly Mazarin F-91385, France.
  • Lafon C; CNS Department, Sanofi, 195 route d'Espagne, F-31036 Toulouse, France.
  • Even L; Medicinal Chemistry, Sanofi, 1 av Pierre Brossolette, Chilly Mazarin F-91385, France.
  • Tsi J; Medicinal Chemistry, Sanofi, 1 av Pierre Brossolette, Chilly Mazarin F-91385, France.
  • Luc TPH; Medicinal Chemistry, Sanofi, 1 av Pierre Brossolette, Chilly Mazarin F-91385, France.
  • Almario A; Medicinal Chemistry, Sanofi, 1 av Pierre Brossolette, Chilly Mazarin F-91385, France.
  • Olivier A; Translational Science, Sanofi, 1 av Pierre Brossolette, Chilly Mazarin F-91385, France.
  • Castel MN; CNS Department, 13, quai Jules Guesde, F-94403 Vitry-sur-Seine Cedex, France.
  • Taupin V; Rare and Neurologic Disease Research, Sanofi, 1 av Pierre Brossolette, Chilly Mazarin F-91935, France.
  • Rooney T; Rare and Neurologic Disease Research, Sanofi, 1 av Pierre Brossolette, Chilly Mazarin F-91935, France.
  • Vigé X; Translational Science, Sanofi, 1 av Pierre Brossolette, Chilly Mazarin F-91385, France.
Bioorg Med Chem Lett ; 29(7): 929-932, 2019 04 01.
Article em En | MEDLINE | ID: mdl-30773432
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Fármacos Neuroprotetores / Membro 2 do Grupo A da Subfamília 4 de Receptores Nucleares Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Fármacos Neuroprotetores / Membro 2 do Grupo A da Subfamília 4 de Receptores Nucleares Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Ano de publicação: 2019 Tipo de documento: Article